Development of a recombinant interleukin-4-pseudomonas exotoxin for therapy of glioblastoma

Toxicologic Pathology

Volumn 27, Issue 1, 1999, Pages 53-57

  Puri, Raj K ^a,b  

^a Center for Biologics Evaluation/Res   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antitumor activity; Cytotoxicity; Glioblastoma; Interleukin 4 receptors; Interleukin 4 Pseudomonas exotoxin; Recombinant chimeric protein; Toxicology

Indexed keywords

CHIMERIC PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 4 RECEPTOR; PSEUDOMONAS EXOTOXIN; RECOMBINANT INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTRATUMORAL DRUG ADMINISTRATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALIA; CAVIA; MACACA FASCICULARIS; MUS MUSCULUS; PSEUDOMONAS; PSEUDOMONAS EXOTOXIN;

EID: 0032979235     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700111     Document Type: Conference Paper

References (28)

1. Debinski W, Puri RK, Kreitman RJ, and Pastan I (1993). A wide range of human cancers express IL-4 receptors that can be targeted with chimeric toxin composed of IL-4 and Pseudomonas exotoxin. J. Biol Chem. 268: 14065-14070.
2. Giri JC, Ahdieh M, Eisenman J, Snanebeck K, Grabstein K, Kumaki S, Naman A, Park LS, Cosman D, and Anderson D (1994). Utilization of β and γ chains of the IL-2 receptor by novel cytokine IL-15. EMBO J. 13: 2822-2830.
3. Husain SR, Bihari N, Kreitman RJ, Pastan I, and Puri RK (1998). Complete regression of established glioblastoma tumor xenografts by interleukin-4 toxin therapy. Cancer Res. 58: 3649-3653.
4. Husain SR, Gill P, Kreitman RJ, Pastan I, and Puri RK (1997). Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Mol. Med. 3: 327-338.
5. Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimpel SD, Din WS, Grabstein KH, Widmer MB, Park LS, Cosman D, and Beckmann MP (1990). Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J. Exp. Med. 171: 861-873.
6. Kondo M, Takeshita T, Ishi N, Nakamura M, Watanabe S, Arai K. and Sugamura K (1993). Sharing of interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science 262: 1874-1877.
7. Kreitman RJ, Puri RK, and Pastan I (1994). A circularly permutated recombinant interleukin-4 toxin with increased activity. Proc. Natl. Acad Sci. USA 91: 6889-6893.
8. Kreitman RJ, Puri RK, and Pastan I (1995). Increased antitumor activity of a circularly permuted IL4-toxin in mice with IL-4 receptor bearing human carcinoma. Cancer Res. 55: 3357-3363.
9. Murata T, Noguchi PD, and Puri RK (1995). Receptors for interleukin (IL)-4 do not associate with the common γ chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J. Biol. Chem. 270: 30829-30836.
10. Murata T, Obiri NI, Debinski W, and Puri RK (1997). Structure of IL-13 receptor: Analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun. 238: 90-94.
11. Murata T, Obiri NI, and Puri RK (1998). Structure of and signal transduction through interleukin 4 and interleukin 13 receptors. Int. J. Mol. Med. 1: 551-557.
12. Murata T, Taguchi J, and Puri RK (1998). Interleukin-13 receptor α′ but not a chain: A functional component of interleukin-4 receptor. Blood 91: 3884-3891.
13. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, and Leonard WJ (1993). Interleukin-2 receptor γ chain: A functional component of interleukin-7 receptor. Science 262: 1877-1880.
14. Obiri NI, Hillman G, Haas GP, Sud S, and Puri RK (1993). Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest. 91: 88-93.
15. Obiri NI, Leland P, Murata T, Debinski W, and Puri RK (1997). The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J. Immunol. 158: 756-764.
16. Obiri NI, Siegel JP, Varricchio F, and Puri RK (1994). Expression and function of high affinity interleukin-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol. 95: 148-155.
17. Pastan I, Chaudahry VK, and FitzGerald DJ (1992). Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 61: 331-354.
18. Pastan I and FitzGerald D (1991). Recombinant toxins for cancer treatment. Science 254: 1173-1177.
19. Paul WE (1990). Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77: 1859-1870.
20. Puri RK (1995). Structure and function of interleukin 4 and its receptors. In: Cytokines: Interleukins and Their receptors, R Kurzrock and M Talpaz (eds). Kluwer, Norwell, Massachusetts, pp. 143-186.
21. Puri RK, Debinski W, Obiri N, Kreitman R, and Pastan I (1994). Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein comprised of human interleukin-4 and Pseudomonas exotoxin. Cell. Immunol. 154: 369-379.
22. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, and Kreitman RJ (1996). Preclinical development of a recombinant toxin containing circularly permuted interleukin-4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 56: 5631-5637.
23. Puri RK, Leland P, Kreitman RJ, and Pastan I (1994). Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the cytotoxic effect of IL-4-Pseudomonas exotoxin chimeric protein. Int. J. Cancer 58: 574-581.
24. c chain in RCC cells does not improve sensitivity. Cell. Immunol. 171: 80-86.
25. Puri RK, Ogata M, Leland P, Feldman GM, FitzGerald D, and Pastan I (1991). Expression of high affinity IL-4 receptors on murine sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between IL-4 and Pseudomonas exotoxin. Cancer Res. 51: 3011-3017.
26. Puri RK and Siegel JP (1993). Interleukin-4 and cancer therapy. Cancer Invest. 11: 473-486.
27. Russell SM, Johnston JA, Noguchi M, Kawamura M, Bacon CM, Friedmann M, Berg M, McVicar DW, Witthuhn BA, Silvennoinen O, Goldmann AS, Schmalstieg FC, Ihle JN, O'Shea JJ, and Leonard WJ (1994). Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: Implications for XSCID and XCID. Science 266: 1042-1045.
28. Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedmann MC, Miyajima A, Puri RK, Paul WE, and Leonard WJ (1993). Interleukin-2 receptor gamma chain: A functional component of the interleukin-4 receptor. Science 262: 1880-1883.